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Abstract
The C-terminal nuclear localization sequence of FUsed in Sarcoma (FUS-NLS) is critical for its nuclear import mediated by
transportin (Trn1). Familial amyotrophic lateral sclerosis (ALS) related mutations are clustered in FUS-NLS. We report here the
structural, biochemical and cell biological characterization of the FUS-NLS and its clinical implications. The crystal structure
of the FUS-NLS/Trn1 complex shows extensive contacts between the two proteins and a unique a-helical structure in the
FUS-NLS. The binding affinity between Trn1 and FUS-NLS (wide-type and 12 ALS-associated mutants) was determined. As
compared to the wide-type FUS-NLS (KD = 1.7 nM), each ALS-associated mutation caused a decreased affinity and the range
of this reduction varied widely from 1.4-fold over 700-fold. The affinity of the mutants correlated with the extent of impaired
nuclear localization, and more importantly, with the duration of disease progression in ALS patients. This study provides
a comprehensive understanding of the nuclear targeting mechanism of FUS and illustrates the significance of FUS-NLS in
ALS.
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Introduction
Fused in sarcoma/translocated in liposarcoma (FUS/TLS) is
a DNA/RNA binding protein that is involved in many processes
of RNA metabolism including gene transcription regulation, RNA
splicing and transport, and translation [1–4]. Wild-type FUS
predominantly resides in the nucleus and shuttles between the
nucleus and cytoplasm [5,6]. In addition to its role in oncogenesis,
mutations in FUS have been recently reported to cause a familial
form of amyotrophic lateral sclerosis (ALS) [7,8]. Abnormal
accumulation of FUS in the cytoplasm and formation of
pathological inclusions are a prominent feature observed in both
familial and sporadic ALS [7–9].
Several laboratories, including ours, have identified the FUS C-
terminal nuclear localization sequence (NLS) and noted that ALS-
associated mutations in FUS are clustered within the NLS
(Figure 1A) [10–12]. The ALS mutations in the FUS-NLS caused
cytoplasmic mis-localization of FUS and induced the formation of
FUS-positive cytoplasmic inclusions. Moreover, nuclear import of
FUS is dependent on the nuclear import protein transportin 1
(Trn1) [11]. It is thus postulated that the point mutations in the
FUS-NLS would block the recognition of FUS by Trn1.
A non-classical PY NLS has been found in other proteins.
Several structures of Trn1 in complex with the PY NLS from
proteins such as hnRNP A1-NLS (PDB code: 2H4M [13]),
hnRNP M-NLS (PDB code: 2OT8 [14]), hnRNP D-NLS and
TAP-NLS (PDB codes: 2Z5N and 2Z5K [15]) have been
determined. Within Trn1, site A (HEAT repeats 8–13) and site
B (HEAT repeats 14–18) are responsible for binding the PY NLS
[15]. The previous studies suggest that PY NLS is structurally
disordered, overall positively charged, and has a central hydro-
phobic or basic motif followed by a C-terminal R/H/KX(2–5)PY
consensus sequence. The last two residues Pro and Tyr are found
to be critical for the Trn1 recognition [13]. Other than the Pro
and Tyr residues, the FUS-NLS shows obvious differences in
amino acid sequences from other known PY NLS’s (Figure 1B).
The FUS-NLS only shares 21%, 28%, 18%, and 12% sequence
identify with hnRNP-A1-NLS, hnRNP-D-NLS, hnRNP-M-NLS,
and TAP-NLS, respectively. Interestingly, the NLS sequence of
FUS is highly conserved among different organisms (Figure 1C).
Thus, we speculate that the FUS-NLS recognition by Trn1 will
possess unique characteristics at the molecular level.
Given the critical significance of the FUS-NLS in regulating its
subcellular localization and in ALS pathology, we determined the
3.0-Å crystal structure of the human Trn1/FUS-NLS complex.
Our results reveal a well folded FUS-NLS that maintains extensive
hydrophobic and electrostatic interactions with Trn1, distinctly
different from other PY NLS’s. We also performed surface
plasmon resonance (SPR) to measure the binding affinity between
Trn1 and wild-type (WT) FUS-NLS or the ALS-associated FUS
mutants. When compared with WT FUS-NLS, each of the ALS-
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associated mutations causes a reduction in the affinity and the
range of this reduction varies from 1.4-fold to 714-fold. Moreover,
the extent of impaired nuclear localization of the ALS mutants
correlates well with the fold reduction in affinity. The results from
this comprehensive characterization of FUS-NLS as well as the
ALS mutations provide critical insights into the nuclear targeting
mechanism of FUS in the context of ALS.
Materials and Methods
Protein Expression and Purification
The full-length human transportin 1 (Trn1, residues 1–890,
a generous gift from Dr. Yuh Min Chook) was subcloned into the
pGEX-4T-3 vector containing a TEV protease-cleavage site and
expressed in E. coli BL21 (DE3) (Novagen, Madison, WI). Protein
purification followed the published protocol [16]. Briefly, cells
were harvested by centrifugation, resuspended in lysis buffer
(50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 20% glycerol, 2 mM
EDTA, 2 mM DTT) and disrupted in a French Pressure Cell.
After centrifugation at 38,900 g for 30 min, the target protein was
purified by glutathione Sepharose 4 Fast Flow (GE Healthcare,
Uppsala, Sweden) and eluted with the lysis buffer plus 20 mM
glutathione. After the removal of the GST-tag by TEV protease
digestion, Trn1 was further purified by two steps of column
chromatography with HiTrap Q FF 5-ml and Superdex 200 HR
10/30 columns (GE Healthcare).
The cDNA encoding the nuclear localization sequence of
human FUS (FUS-NLS, residues 495–526) was amplified by PCR
using the GFP-FUS plasmid template we previously published
[10] and subcloned into pGEX-6P-2 to include an N-terminal
GST tag. The GST-FUS-NLS fusion protein was expressed in
E. coli Rosetta (DE3) (Novagen) and purified similarly as for Trn1.
Figure 1. Sequence analysis of FUS-NLS. (A). Domain structure of FUS with the C-terminal NLS. The ALS mutations are clustered in the NLS and
the mutations studied here are shown in red. (B) Amino acid sequence alignments of FUS-NLS with other PY NLS’s from hnRNP A1, hnRNP D, hnRNP
M and TAP. (C). Sequence alignment of FUS-NLS from different organisms.
doi:10.1371/journal.pone.0047056.g001
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The difference is (i) after glutathione-affinity column, PreScission
protease (GE Healthcare) was applied to cleave the fusion FUS-
NLS on-column for 4 hr at 4uC, followed by elution with lysis
buffer. (ii) After cleavage, the eluted FUS-NLS was further purified
by gel filtration chromatography with a Superdex 200 HR 10/30
column (GE Healthcare). Mutations in FUS-NLS were generated
by site-directed mutagenesis and the mutant proteins were
expressed and purified as described above.
To prepare the Trn1/FUS-NLS complex, purified Trn1 and
FUS-NLS were mixed in a molar ratio of 1:2 and kept on ice for
2 h. The Trn1/FUS-NLS complex was then concentrated to
5 mg/ml for crystallization.
Crystallization, Data Collection, and Structure
Determination
Hanging drops were made by mixing a solution (2 ml)
containing the FUS-NLS/Trn1 complex (5 mg/ml protein in
20 mM HEPES, pH 7.3, 110 mM potassium acetate, 10 mM
DTT) with an equal volume of reservoir solution containing
640 mM potassium-sodium tartrate and 20 mM HEPES buffer,
pH 7.4. Crystals with a size of 200 mm 6 50 mm 6 10 mm
were grown at 289uK within two weeks. Harvested crystals were
cryoprotected with a reservoir solution supplemented with 26%
(v/v) glycerol and then mounted for flash-cooling at 100uK.
Diffraction data were collected at the beamline BL17U1 of
Shanghai Synchrotron Radiation Facility (SSRF) (Shanghai,
China) using an MX225 CCD detector. Data processing and
reduction were carried out using the HKL2000 package [17].
The structure of the FUS-NLS/Trn1 complex was solved first
by molecular replacement with Molrep from CCP4 suite [18]
using the atomic coordinates of human Trn1 (PDB code: 2Z5J)
[15] as a search model. Molecular-replacement solutions were
modified and refined with alternate cycles of manual refitting
and building into a 2Fo 2 Fc composite omit electron density
map using Coot [19] and simulated annealing and maximum
likelihood protocols using CNS [20], REFMAC [21], and
phenix.refine [22]. The final model of the complex was checked
for geometrical correctness with PROCHECK [23]. In the final
model, the electron densities for residues 1–4 and 323–371 of
the Trn1 and residues 495–507 of the FUS-NLS were invisible,
and these 66 residues were excluded from the model.
Furthermore, because of the poor electron densities for the
side chains of residues K6, D8, R870 and R871 in Trn1, these
4 residues were mutated to Alanine in the model.
Cartoon and surface representations were generated using
PyMOL. The electrostatic potential was calculated and displayed
with PyMOL. The atomic coordinates and structural factors for
the human Trn1/FUS-NLS complex have been deposited in the
Protein Data Bank (PDB) database with accession code 4FQ3.
Surface Plasmon Resonance Analysis (SPR)
All surface plasmon resonance experiments were carried out
using a BIAcore 3000 biosensor (GE Healthcare) at 25uC. Trn1
was immobilized on a CM5 sensor chip by the amino coupling
method to give about 8600 Resonance Unit (RU). WT and mutant
FUS-NLS were prepared in the running buffer (20 mM HEPES,
pH 7.3, 110 mM potassium acetate, 2 mM magnesium acetate,
2 mM EGTA, 2 mM DTT, 10% glycerol and 0.005% [v/v]
Tween 20) and injected at increasing concentrations at a flow rate
of 50 ml/min. The association was allowed to proceed for 60 sec,
and the dissociation of the complex was monitored for 60–360 sec.
Regeneration of the chip was done with 25 ml of 2 M NaCl
followed by 50 ml of the running buffer.
For the WT FUS-NLS and mutants G507D, S513P, G515C,
R518K, R521G, E523S and R524S, the 1:1 Langmuir model was
applied to fit the experimental results to calculate the affinity (KD)
and kinetics (ka and kd) of the FUS-NLS/Trn1 binding. For
mutants K510E, R514G, H517P, R518G, R522G, P525L and
Y526A, the interaction with Trn1 was weak and the kd was too fast
to be fit. Thus, the KD values of these weak interactions were
calculated by plotting the steady state equilibrium binding as
a function of the concentration of the injected proteins. The
correlation coefficient x2 value is a statistical measure of how
closely the fitted curve fits the experimental data. In general, x2
values lower than about 10 signify a good fit [15].
In the particular case of the E523Y mutant, its binding to Trn1
was so tight that the dissociation of the complex was not observed
under the experimental conditions (Figure S3). Thus, we were
unable to obtain the affinity and kinetics constants of the
interaction of Trn1 with the E523Y mutant of FUS-NLS.
Confocal Microscopy
Confocal microscopy was used to examine the subcellular
localization of WT full-length human FUS and 5 different ALS
mutants (S513P, G515C, R521G, R522G and P525L). Neuro-
blastoma 2a (N2a) cells were seeded into 12-well plate with gelatin-
coated 18-mm coverslips inside. Various GFP-FUS constructs
were generated and transfected into N2a cells using Lipofectamine
2000 (Invitrogen) as previously published [24]. Alternatively,
primary dorsal root ganglion (DRG) neurons were prepared and
used as previously published [10]. 24 hours after transfection, cells
were fixed in 4% paraformaldehyde, permeabilized by 0.1%
Triton X-100. The nuclei were stained by 49,6-diamidino-2-
phenylindole (DAPI). The coverslips were mounted and images
were acquired using an Olympus confocal microscope (Olympus
Fluoview, Ver.1.7c).
Results
Extensive Interaction between FUS-NLS and Trn1 in the
Trn1/FUS-NLS Complex
The structure of the binary complex consisting of human Trn1
(residues 1–890) and human FUS-NLS (residues 495–526) was
determined by X-ray crystallography (PDB code: 4FQ3). The
orthorhombic crystal (space group P21212) contains one complex
per asymmetric unit. The data-collection and refinement statistics
are summarized in Table S1.
Within the complex, the structure of Trn1 is highly helical and
forms a perfect right-handed solenoid structure with 20 HEAT
repeat domains (Figure 2A), which is similar to what have been
published [13–15]. A C-terminal arch formed by HEAT repeats
8–18 of Trn1 is responsible for binding with FUS-NLS. When the
Trn1 structure determined in this study (PDB code: 4FQ3) was
superimposed onto that in the Trn1/hnRNP A1-NLS, Trn1/
hnRNP D-NLS, Trn1/hnRNP M-NLS and Trn1/TAP-NLS
complexes (PDB codes: 2H4M, 2Z5N, 2OT8 and 2Z5K) [13–15],
the atomic r.m.s.d. values are 6.05 Å, 3.15 Å, 3.62 Å and 3.31 Å,
respectively.
FUS-NLS forms a well-organized structure in the complex in
this study (Figure 2B) as compared to other PY NLS’s with no
specific secondary structure in previous studies. In particular, the
a-helix (R514–R521) within FUS-NLS is not formed in other PY
NLS’s (Figure 2C). These structural features facilitate the extensive
interactions with Trn1. Based on the structural features and the
nature of the interaction, we divide FUS-NLS into three regions:
region I (E523–Y526), region II (D512–R522), and region III
FUS-NLS/Transportin 1 Complex Structure and ALS
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(P508–M511). These regions and the Trn1 residues they interact
with are shown in Figure 3A.
Region I of FUS-NLS is involved in docking into the PY-motif
recognition pocket in Trn1 through hydrophobic contacts.
Residues E523, P525, and Y526 of FUS-NLS are in contact with
K377, A381, L419, I457, W460 and A499 in Trn1 (Figure 3B,
S1A and Table S2). In addition, a hydrogen bond between Y526
of the FUS-NLS and D384 of Trn1 further enhances the
interaction (Figure 3A and Table S3).
Region II of FUS-NLS is unique as it forms an a-helix structure
that cannot be found in other PY NLS’s (Figure 2C). The helical
structure makes the side chains of R514, H517, R518, R521 and
R522 face outwards, displaying a continuously positively charged
patch (Figure S1B and S1D). These 5 positively charged residues
of FUS-NLS are involved in polar and electrostatic interactions
with acidic and polar residues (T506, E509, D543, D550, E588,
S591, S592 and D646) on the surface formed by HEAT Repeats
11–14 of Trn1 (Figures 3A, S1B and Table S3).
Region III of FUS-NLS interacts with Trn1 mainly through
hydrophobic interactions. Residues P508, K510 and M511 in
FUS-NLS are in contact with residues N726, N727, W730, T766
and I804 in Trn1 (Figures 3C, S1C and Table S2). In addition,
hydrogen bonds and ion pairs between residues G509 and K510
in FUS-NLS and residues N726, N770, and D693 in Trn1 also
contribute to the interaction (Figure 3A and Table S3).
The extensive contacts between FUS-NLS and Trn1 are
generally categorized as hydrophobic and polar/electrostatic
interactions and summarized in Tables S2 and S3, respectively.
It becomes evident that regions I and III interact with Trn1 mainly
by hydrophobic forces and region II by polar/electrostatic
interaction.
Structural Characteristics of the C-terminal PY-fragment
of FUS-NLS
The perfect docking of the PY-containing region I of FUS-NLS
into the hydrophobic PY-motif recognition pocket of Trn1 is
critical. To form the specific conformation required for docking to
Trn1, the hydrophobic patch formed by the hydrophobic parts of
the side chains of E524, P525 and Y526 residues is required.
Figure S2A shows the superimposition of region I (E523–R524–
P525–Y526, the PY motif) of FUS-NLS with the corresponding
motif in hnRNP D-NLS (Y352–K353–P354–Y355; PDB code:
2Z5N), hnRNP M-NLS (F61–E62–P63–Y64; PDB code: 2OT8),
hnRNP A1-NLS (S286–G287–P288–Y289; PDB code: 2H4M)
and TAP-NLS (Y72–N73–P74–Y75; PDB code: 2Z5K). It is
evident that the structure of this motif is highly conserved. At the
sequence level, although P525 and Y526 are absolutely conserved,
the other two residues vary substantially among the five PY NLS’s.
The R524 residue in FUS-NLS is unique in that it provides
additional steric constraints for region I by forming hydrogen
bonds with neighboring residues. As shown in Figure 3D, the
hydrogen bonds between R524(Ng1) and R522(O), R524(Ng2)
and D520(O), and R524(Ng1) and Q519(O) assist region I to
maintain a rigid conformation. In contrast, G287 in hnRNP A1
(Figure S2A) and N73 in TAP (Figure S2B) form none or 1
hydrogen bond in their structures, respectively. The combination
of P525 and R524 makes the PY-motif (region I) a rigid structure
that is optimized for recognition by Trn1.
Binding Affinity of Wild-type and Mutant FUS-NLS with
Trn1
To quantitatively analyze the binding affinity between FUS-
NLS and Trn1, we performed surface plasmon resonance (SPR) to
measure the dynamics of the interaction between FUS-NLS and
Figure 2. The structure of the FUS-NLS/Trn1 complex. (A) The overall structure. (B) The 2Fo 2 Fc composite omit electron density map around
the FUS-NLS fragment (residues 508–526) contoured at 1.0 s (gray mesh). The Trn1 and the FUS-NLS are shown in cyan and yellow, respectively. (C)
The superimposition of residues 508–526 of FUS-NLS (yellow; PDB code: 4FQ3) with the corresponding regions from hnRNP A1-NLS (blue; PDB code:
2H4M), hnRNP D-NLS (grey; PDB code: 2Z5N), hnRNP M-NLS (magenta; PDB code: 2OT8), and TAP-NLS (cyan; PDB code: 2Z5K). The a-helix is unique in
FUS-NLS whereas no specific secondary structure was found in the other structures.
doi:10.1371/journal.pone.0047056.g002
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Trn1. In addition to wild-type FUS-NLS (referred as WT), we also
measured 12 ALS-associated mutants: G507D, K510E, S513P,
R514G, G515C, H517P, R518G, R518K, R521G, R522G,
R524S and P525L [7,8]. Three additional mutations were
designed based on the structural insights from this study (E523S,
Figure 3. The interactions between the Trn1 and the FUS-NLS. (A) Summary of the polar/electrostatic interactions between FUS-NLS (yellow)
and Trn1 (cyan). FUS-NLS is divided into region I (E523–Y526), region II (D512–R522), and region III (P508–M511). (B) Schematic illustration of the
hydrophobic contacts between the region I of FUS-NLS (E523–R524–P525–Y526) and Trn1. (C) Schematic illustration of the hydrophobic contacts
between the region III of FUS-NLS (P508–G509–K510–M511) and Trn1. (D). The interaction between R524 and Q519, D520 and R522 within FUS-NLS.
The figure is prepared with LIGPLOT [38].
doi:10.1371/journal.pone.0047056.g003
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E523Y and Y526A) and have not been found in familial ALS
patients yet.
The SPR results for WT FUS-NLS and all mutants are
summarized in Table 1. The binding affinity between WT and
Trn1 is strong with a dissociation constant (KD) of 1.7610
29 M.
All 12 ALS-associated point mutations reduced the binding affinity
and the reduction varies widely in the range of 1.4- to 714-fold.
Among the ALS mutations, P525L reduces the affinity most
significantly (more than 7006 reduction) followed by R522G
(,2006 reduction). In contrast, S513P or G515C only causes
a slight decrease of the binding affinity (less than 26 reduction).
When mutation occurs to the positive residues in the a-helix of
region II, each of the single mutation (R514G, H517P, R518G,
R521G and R522G) caused significant reduction (from ,86 to
2046) in the binding affinity (Table 1).
Based on the structure of the FUS-NLS/Trn1 complex, we
designed three additional mutants (Y526A, E523S and E523Y)
and measured their binding affinity with Trn1. Y526A causes
,5006 reduction in the affinity, which is expected since Y526 is
critical in the PY NLS. E523 is interesting since it is the most
variable residue in region I (Figure S2A). The Cd of E523 is
involved in a hydrophobic interaction with Ca and Cb of A499 in
Trn1 (Table S2). We predicted that E523Y could enhance the
interaction and that E523S could reduce the affinity. In the SPR
analysis, the E523Y mutant bound with Trn1 on the chip so
strongly that it could not be dissociated (Figure S3), thus we could
not obtain the dissociation constant. On the other hand, E523S
mutation indeed caused ,20% reduction in the KD value.
Impairment of Nuclear Targeting is Correlated with FUS-
NLS/Trn1 Binding Affinity
The regulation of subcellular localization of FUS is critical to
maintain its proper function and the aberrant cytoplasmic
accumulation of FUS is a prominent feature in ALS. We
rationalize that ALS mutations with different reduction levels in
the FUS-NLS/Trn1 binding affinity will have different effects on
the subcellular localization of FUS in vivo. We tested this hypothesis
by examining the subcellular localization of WT, P525L, R522G,
R521G, S513P and G515C full-length FUS in N2A cells as well as
primary neurons. As shown in Figure 4, WT FUS is pre-
dominantly inside the nucleus. For the P525L and R522G
mutations that disrupt the FUS-NLS/Trn1 binding most signif-
icantly, the mutant FUS is predominantly outside the nucleus and
forms cytoplasmic inclusions. For the S513P and G515C
mutations that minimally disrupt the FUS-NLS/Trn1 binding,
the mutant FUS is still predominantly inside the nucleus. For
R521G that causes approximately 156 reduction in the FUS-
NLS/Trn1 binding, the mutant protein is localized in both the
nucleus and cytoplasm. Similar results were obtained in the
primary dorsal root ganglia (DRG) neurons (Supplementary
Figure S4). The results support that the disruption of nuclear
targeting is closely correlated with the fold of reduction in the
FUS-NLS/Trn1 binding.
Correlation between FUS-NLS/Trn1 Binding Affinity and
ALS Disease Duration
We further asked whether the FUS-NLS/Trn1 binding affinity
can possibly correlate with the ALS disease manifestation in
human patients. The durations of the disease from onset in the
familial ALS patients carrying different FUS mutations were
compiled from published studies [7,25–28] and plotted against the
relative affinity of the corresponding mutant from Table 1. As
shown in Figure 5, the disease duration correlates very well with
the relative affinity and the coefficient of determination R2 is 0.88.
It is suggested that the greater disruption in FUS-NLS/Trn1
interaction, the greater level of FUS mis-localization, and the more
rapid disease progression in the patient carrying the particular
mutation.
Table 1. Association rate, dissociation rate, and equilibrium dissociation constants of Trn1 and wild-type and mutant FUS-NLS.
Immobilized Analyte ka (M
21s21) kd (s
21) KD (M) Relative affinity
a x2
FUS-NLS(WT) 2.36106 3.761023 1.761029 1 10.3
FUS-NLS(S513P) 9.46106 2.361022 2.461029 0.71 5.78
FUS-NLS(G515C) 1.86106 5.161023 2.861029 0.61 7.84
FUS-NLS(G507D) 5.76106 4.461022 7.861029 0.22 2.04
FUS-NLS(R524S) 5.66106 5.861022 1.061028 0.17 1.75
FUS-NLS(R518K) 6.06106 7.861022 1.361028 0.13 2.85
FUS-NLS(R521G) 1.46105 3.461023 2.561028 0.068 17.30
Trn1 FUS-NLS(R514G) 6.761028 0.025 2.85
FUS-NLS(H517P) 1.461027 0.012 5.14
FUS-NLS(R518G) 1.561027 0.011 0.97
FUS-NLS(K510E) 1.561027 0.011 9.79
FUS-NLS(R522G) 3.561027 0.0049 0.78
FUS-NLS(P525L) 1.261026 0.0014 2.67
FUS-NLS(Y526A) 8.961027 0.0019 11.70
FUS-NLS(E523S) 5.56103 1.161025 2.061029 0.85 5.50
FUS-NLS(E523Y) – – – –
The 12 ALS mutations are organized in the order of decreasing affinity.
aThe relative affinity is defined as KD of WT (M) divided by KD of the FUS-NLS mutants (M).
The correlation coefficient x2 value is a statistical measure of how closely the fitted curve fits the experimental data [15] (see Methods).
doi:10.1371/journal.pone.0047056.t001
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Discussion
This study describes a structural, biochemical and cell biological
characterization of FUS-NLS that we and others previously
identified [10–12]. We first determined the crystal structure of the
FUS-NLS/Trn1 complex, and then measured the binding affinity
of WT and mutant FUS-NLS to Trn1. We also examined the
subcellular localization of WT and mutant full-length FUS and
showed a strong correlation between the reduced binding affinity
and increased FUS mis-localization. We last discuss the implica-
tion of this study in understanding ALS etiology and future
therapeutic development.
As discussed earlier, cytoplasmic accumulation and pathological
inclusions of FUS are prominent features in ALS. The RNA and
DNA targets of FUS have been reported recently [29,30] and the
nucleic acid binding also requires the nuclear localization of FUS.
The data suggest that it is critical to understand the detailed
nuclear targeting mechanism.
Although there are some similarities, the interaction of FUS-
NLS with Trn1 differs in many ways from that of Trn1 with other
PY NLS’s in previous studies [13–15]. FUS-NLS forms extensive
contact with Trn1 and we categorized the FUS-NLS into three
regions based on the nature of the interaction: region I (PY-
fragment), region II (the helical region) and region III (the
hydrophobic motif). Region I and III mainly interact with Trn1 by
hydrophobic interaction (Figures 3B, 3C, S1A, S1C and Table S2)
whereas region II mainly by polar/electrostatic interaction
(Figure 3A and Table S3). These extensive interactions account
for the underlying mechanism for the high affinity binding of FUS-
NLS to Trn1 (KD = 1.7 nM).
The most remarkable distinction between FUS-NLS and other
PY NLS’s is the a-helix in region II (Figure 2B and 2C). This a-
helix exposes all positively charged residues (R514, H517, R518,
R521 and R522) in the region, which allows them to form
electrostatic contacts with the negatively charged surface of Trn1
(Figure S1B and S1D). Consequently, the ALS-associated muta-
tions in this region (R514G, H517P, R518G, R521G and R522G)
caused significantly decreased binding affinity with Trn1 (,86 to
2046 reduction).
Figure 4. Subcellular localization of WT and mutant FUS. GFP-tagged WT full-length human FUS or different ALS mutants (S513P, G515C,
R521G, R522G and P525L) were transfected into N2a cells. The cells were fixed in 4% paraformaldehyde and permeabilized by 0.1% Triton X-100 24
hours after transfection. The nuclei were stained by 49,6-diamidino-2-phenylindole (DAPI). The coverslips were mounted and images were acquired
using an Olympus confocal microscope (Olympus Fluoview, Ver.1.7c).
doi:10.1371/journal.pone.0047056.g004
Figure 5. Correlation between the disease duration of familial
ALS patients carrying R518K, R521G, R524S and P525L
mutations and the relative binding affinity of the mutant
proteins to Trn1. The coefficient of determination R2 is 0.88,
suggesting strong correlation. The number of patients for the R518K,
R521G, R524S and P525L mutations are 12, 4, 2, and 8, respectively.
doi:10.1371/journal.pone.0047056.g005
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Within the short region I (the PY fragment, E523-Y526), P525
and Y526 are the most important residues. The ALS mutation
P525L and the Y526A mutation we generated both dramatically
decreased the binding affinity. In addition, FUS-NLS utilizes E523
and R524 to maintain the specific conformation of the PY
fragment that will allow the optimized interaction/recognition.
E523 is unique in that its Cd forms hydrophobic interaction with
Ca and Cb of A499 in Trn1 (Table S2). There is no ALS-
associated mutation reported on E523 yet. As described earlier,
R524 forms three pairs of hydrogen bonds with R522, D520 and
Q519 (Figure 3D), which significantly enhances the rigidity of the
PY fragment to facilitate the interaction with Trn1. Such features
are not observed in other PY NLS’s. Consequently, the ALS
mutation R524S causes an approximately 66 reduction in the
binding affinity (Table 1) although R524 does not directly interact
with Trn1. This suggests that R524 and the hydrogen bonds it
forms are important. As a comparison, S513 and G515 are also
not directly involved in the FUS-NLS/Trn1 interaction and
S513P and G515C only cause less than 2-fold reduction in the
binding affinity (Table 1).
It is noted that the FUS-NLS is highly conserved in many
organisms (Figure 1C). It is logical that the NLS is critical to the
proper subcellular localization and function of FUS. Our sub-
cellular localization results from WT full-length FUS and five
different ALS-associated mutants clearly demonstrated the corre-
lation between binding affinity and nuclear targeting efficiency
(Figure 4). When a mutation causes greater reduction in the FUS-
NLS/Trn1 binding affinity, it will induce greater cytoplasmic
accumulation of FUS. Different ALS-associated mutants showing
varied FUS-NLS/Trn1 binding affinities caused different extents
of cytoplasmic accumulation.
This logically leads to a critical question: is the binding affinity
possibly correlated with the ALS disease manifestation in human
patients? We have shown that the disease duration correlates very
well with the relative affinity (Figure 5), suggesting that the greater
disruption in the FUS-NLS/Trn1 interaction, the greater level of
FUS mis-localization, and the more rapid disease progression in
the patient carrying the particular mutation. In another study that
reported S513P and H517P mutations [31], the onset in patients
with the S513P mutation (the mutation that causes a minimal
disruption in FUS-NLS/Trn1 binding) was around 60 years old as
compared to 30 years in patients with the H517P mutation
(reduced the binding affinity 836). In addition, the case with the
S513P mutation progressed slowly, but specific disease duration
data were not reported [31]. These clinical observations are
consistent with our results that S513P only minimally decreased
the FUS-NLS/Trn1 binding affinity (,30% reduction). More-
over, in the extreme cases of the FUS truncation mutant R495X
that lacks the NLS, studies showed juvenile onset and rapid
progression in these patients [26,28]. The results support the
critical importance of the NLS in maintaining normal FUS
function under physiological conditions as well as the severe
consequence of disrupting the NLS in ALS under pathological
conditions.
It is noted that the clinical data are limited (a total of 26 patients
carrying four different FUS mutations were plotted in Figure 5)
and scattered in the literature and that more clinical data are
needed to examine whether the correlation applies to other
mutations. In addition to the intrinsic properties of FUS, it is
conceivable that other factors could have significant impact on the
FUS localization, downstream pathways and ultimate clinical
manifestation in patients. Potential factors include environment
(lifestyle, stresses) and ageing. It is possible that ageing related
changes could augment the mislocalization of mutant FUS, even
the mutations that have minor reduction in their binding affinity to
Trn1 (e.g. S513P and G515C). It is also possible that the stress
granules induced by mutant FUS [10–12] could exacerbate
cytoplasmic accumulation of mutant FUS. These remain to be
determined in future studies.
A related question is whether the relative affinity of mutant FUS
is correlated with the age of disease onset/diagnosis. Despite the
pair-wise comparison discussed above, systematic analysis of
patients carrying S513P, H517P R518K, R521G, R524S and
P525L mutations showed no apparent correlation between the
disease onset age and the relative affinity of mutant FUS
(R2 = 0.40, data not shown). It is known that ALS is a non-cell
autonomous disease and the disease onset and progression are
influenced by different cell types in central nerve system in the
mouse models of mutant SOD1 mediated ALS [32–35]. It remains
to be elucidated what factors determine the disease onset and
progression in FUS mediated familial ALS.
As for future therapeutic development, the implication of this
study is to provide a detailed structural basis for designing
potential small molecules that can modulate the FUS-NLS/Trn1
interaction so that the disruption of the ALS mutation can be
minimized. A similar strategy has been used to design an inhibitor
of nuclear import [14], thus it is conceivable that our structural
data can benefit the design of compounds that can enhance
nuclear import. Such small molecules that can minimize the
disruptive effect of the ALS mutations could be tested first in
model organisms such as Drosophila [36], potentially providing
a new avenue for ALS treatment.
In the final days of finishing this manuscript, a FUS-NLS/Trn1
complex structure was published online [37]. The unique a-helical
structure in FUS-NLS is also noted in that study. The binding
affinity between wild-type FUS-NLS and Trn1 was consistent in
the nM range although different techniques were used in the two
studies. We measured the binding affinities for more ALS mutants
and found that some mutations decreased the affinity more
drastically. For instance, the interaction between P525L mutant
FUS-NLS and Trn1 was found to decrease more than 700 fold in
our study whereas the decrease was only 9 fold in the other study.
This could potentially be due to the fact that different techniques
were used; we used SPR and the other study used isothermal
titration calorimetry (ITC). The correlation between the decreased
affinity and the subcellular localization (Figure 4) as well as the
ALS disease progression (Figure 5) is discussed in depth in our
study.
Supporting Information
Figure S1 The surface electrostatic potential of Trn1 at
the binding site interacting with region I (A), region II
(B) and region III (C) of FUS-NLS. The surface interacting
with region I and region III are largely neutral whereas the surface
interacting with region II is highly negatively charged. FUS-NLS
was shown in yellow. (D) The surface properties of the FUS-NLS.
The positively charged surface in region II interacts with the
corresponding negatively charged surface in Trn1. The potential
displayed represents a range from 215 (red) to +15 (blue) kBT.
(PDF)
Figure S2 Structural properties of the PY fragments of
the FUS-NLS (region I) and the other PY-NLS’s. (A)
Structural alignment of the PY fragments of the FUS-NLS (yellow;
PDB code 4FQ3), hnRNP A1-NLS (blue; PDB code 2H4M),
hnRNP D-NLS (grey; PDB code 2Z5N), hnRNP M-NLS
(magenta; PDB code 2OT8), and TAP-NLS (cyan; PDB code
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2Z5K). (B) N73 and R71 of the TAP-NLS form one intramole-
cular hydrogen bond.
(PDF)
Figure S3 SPR analysis of WT and E523Y mutant NLS
binding with Trn1. The E523Y mutant bound to Trn1 so
tightly that the dissociation of the complex was not observed under
the experimental conditions.
(PDF)
Figure S4 Subcellular localization of WT and mutant
FUS in primary mouse dorsal root ganglion (DRG)
neurons. GFP-tagged WT full-length human FUS or different
ALS mutants (G515C, R522G and P525L) were transfected into
DRG neurons. Cells were fixed and permeabilized 48 hours after
transfection. The nuclei were stained by 49,6-diamidino-2-
phenylindole (DAPI). The coverslips were mounted and images
were acquired using an Olympus confocal microscope.
(PDF)
Table S1 Summary of data-collection and refinement
statistics.
(PDF)
Table S2 Summary of hydrophobic contacts between
Trn1 and FUS-NLS.
(PDF)
Table S3 Summary of polar/electrostatic interactions
between Trn1 and FUS-NLS.
(PDF)
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